Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: November 24, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of an exhibit rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document serves to incorporate an exhibit by reference into existing Registration Statements (Form S-8 and Form F-3).
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Risks and Contingencies: None explicitly detailed in this filing.
Unusual Items: The filing discloses the submission of Exhibit 99.1, an "Initial Director's Interest Notice" for Julian Babarczy.
Investor Verification Checklist
- Verify the details of the "Initial Director's Interest Notice" for Julian Babarczy referenced in Exhibit 99.1.
- Confirm the status of the Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076) into which this report is incorporated.
- Review the company's most recent Form 20-F for actual financial performance data, as this Form 6-K contains no financial metrics.